68Ga-MY6349 PET/CT imaging to assess Trop2 expression in multiple types of cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study introduces 68Ga-MY6349 PET/CT, a new imaging tool for assessing trophoblast cell-surface antigen 2 (Trop2) expression in various cancers. The tracer shows promise for improved cancer diagnosis, staging, and personalized treatment decisions.
Area Of Science
- Oncology
- Radiochemistry
- Molecular Imaging
Background
- Trophoblast cell-surface antigen 2 (Trop2) is overexpressed in many epithelial cancers, making it a potential therapeutic and diagnostic target.
- A novel Trop2-specific radiotracer, 68Ga-MY6349, has been developed for positron emission tomography/computed tomography (PET/CT).
Purpose Of The Study
- To evaluate the clinical utility of 68Ga-MY6349 PET/CT in a prospective trial across 15 cancer types.
- To compare the diagnostic performance of 68Ga-MY6349 PET/CT with established imaging modalities like 18F-FDG PET/CT and 68Ga-PSMA-11 PET/CT.
Main Methods
- A prospective translational study involving 90 patients with 15 different cancer types undergoing 68Ga-MY6349 PET/CT.
- Paired imaging was performed in 78 patients (68Ga-MY6349 vs. 18F-FDG PET/CT) and 12 prostate cancer patients (68Ga-MY6349 vs. 68Ga-PSMA-11 PET/CT).
- Immunohistochemistry was used to correlate Trop2 expression levels with radiotracer uptake.
Main Results
- 68Ga-MY6349 PET/CT demonstrated high, albeit heterogeneous, tumor uptake across various cancer types, correlating well with Trop2 expression levels.
- The tracer showed superior tumor uptake compared to 18F-FDG PET/CT in breast, prostate, and thyroid cancers.
- In prostate cancer, 68Ga-MY6349 PET/CT offered comparable lesion uptake but improved tumor-to-background contrast over 68Ga-PSMA-11 PET/CT, revealing more metastatic lesions.
Conclusions
- 68Ga-MY6349 PET/CT serves as a noninvasive method for assessing tumor Trop2 expression.
- This imaging approach can enhance cancer diagnosis, staging, and guide personalized treatment strategies, particularly for Trop2-targeted therapies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Radioactive Tracer: PET involves using biologically active molecules labeled with radioactive isotopes, known as tracers or radiotracers. The...
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...